EP1789069A4 - Cyclic peptides for treatment of cachexia - Google Patents

Cyclic peptides for treatment of cachexia

Info

Publication number
EP1789069A4
EP1789069A4 EP05771593A EP05771593A EP1789069A4 EP 1789069 A4 EP1789069 A4 EP 1789069A4 EP 05771593 A EP05771593 A EP 05771593A EP 05771593 A EP05771593 A EP 05771593A EP 1789069 A4 EP1789069 A4 EP 1789069A4
Authority
EP
European Patent Office
Prior art keywords
cachexia
treatment
cyclic peptides
peptides
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05771593A
Other languages
German (de)
French (fr)
Other versions
EP1789069A2 (en
Inventor
Shubh D Sharma
Ramesh Rajpurohit
Kevin B Burris
Yi-Qun Shi
Annette M Shadiack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of EP1789069A2 publication Critical patent/EP1789069A2/en
Publication of EP1789069A4 publication Critical patent/EP1789069A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP05771593A 2004-07-06 2005-07-06 Cyclic peptides for treatment of cachexia Withdrawn EP1789069A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58597104P 2004-07-06 2004-07-06
US11/174,845 US7342089B2 (en) 2001-07-11 2005-07-05 Cyclic peptides for treatment for cachexia
PCT/US2005/024125 WO2006014552A2 (en) 2004-07-06 2005-07-06 Cyclic peptides for treatment of cachexia

Publications (2)

Publication Number Publication Date
EP1789069A2 EP1789069A2 (en) 2007-05-30
EP1789069A4 true EP1789069A4 (en) 2011-01-26

Family

ID=35787651

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05771593A Withdrawn EP1789069A4 (en) 2004-07-06 2005-07-06 Cyclic peptides for treatment of cachexia

Country Status (6)

Country Link
US (1) US7342089B2 (en)
EP (1) EP1789069A4 (en)
JP (1) JP2008505915A (en)
AU (1) AU2005269920A1 (en)
CA (1) CA2573142A1 (en)
WO (1) WO2006014552A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
JP2010539231A (en) * 2007-09-17 2010-12-16 ビオネリス・アクチボラゲット Methods and means for the treatment of cachexia
EA018630B1 (en) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA020959B1 (en) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
EA201290295A1 (en) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. SPECIFIC TO MELANOCORTIN-1 RECEPTOR LINEAR PEPTIDES
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US9200160B2 (en) * 2010-03-29 2015-12-01 Momentive Performance Materials Inc. Silylated polyurethane/polyorganosiloxane blend and sealant composition and fumed silica composition containing same
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
RU2725150C2 (en) * 2013-03-15 2020-06-30 Ритм Фармасьютикалз, Инк. Peptide compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035952A2 (en) * 1998-12-14 2000-06-22 Melacure Therapeutics Ab Compounds for control of eating, growth and body weight
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
JP3219096B2 (en) * 1990-05-10 2001-10-15 ニコメド ファーマ エイエス Pharmaceutical preparations containing n-glycolfurols and n-ethylene glycols
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5908609A (en) * 1996-06-10 1999-06-01 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
WO1998020121A1 (en) * 1996-11-06 1998-05-14 Children's Medical Center Corporation Transgenic animal expressing a syndecan in the regions of hypothalamus
EP0959873B1 (en) * 1996-12-20 2006-03-01 ALZA Corporation Gel composition and methods
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
KR100519201B1 (en) * 1999-03-29 2005-10-06 더 프록터 앤드 갬블 캄파니 Melanocortin receptor ligands
US6329670B1 (en) * 1999-04-06 2001-12-11 Micron Technology, Inc. Conductive material for integrated circuit fabrication
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CA2396307A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US20030032791A1 (en) * 2000-06-26 2003-02-13 Alan Robertson Scott Novel melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate
US20030113263A1 (en) * 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
WO2000035952A2 (en) * 1998-12-14 2000-06-22 Melacure Therapeutics Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
US20060014676A1 (en) 2006-01-19
EP1789069A2 (en) 2007-05-30
WO2006014552A3 (en) 2006-12-14
US7342089B2 (en) 2008-03-11
CA2573142A1 (en) 2006-02-09
WO2006014552A2 (en) 2006-02-09
JP2008505915A (en) 2008-02-28
AU2005269920A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
EP1789069A4 (en) Cyclic peptides for treatment of cachexia
EP1781316A4 (en) Cyclic peptides for treatment of cachexia
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
EP1744751A4 (en) Methods for the treatment of synucleinopathies
EP1809265A4 (en) Methods for the treatment of synucleinopathies
AP2009004840A0 (en) Compounds and methods for treatment of HCV
GB0404656D0 (en) Treatment of spinal conditions
EP1732549A4 (en) Methods for the treatment of synucleinopathies
IL182993A0 (en) Treatment of mastitis
ZA200610736B (en) Treatment of hydrocarbons
PL1709070T3 (en) Peptides for treatment of autoimmune diseases
EP1740198A4 (en) Anti-aging effects of substance p
EP1793813A4 (en) Treatment of adhd
GB0426196D0 (en) Methods of treatment
IL178517A0 (en) Therapeutic peptides
ZA200701039B (en) Cyclic peptides for treatment of cachexia
GB0425854D0 (en) Therapeutic treatment
GB0408521D0 (en) Treatment of sepsis
GB0625234D0 (en) Treatment of Hydrocarbons
GB0418393D0 (en) Treatment of cachexia
GB0423173D0 (en) Treatment of diabetes
ZA200609395B (en) Therapeutic peptides
ZA200902434B (en) Compounds and methods for treatment of HCV
GB0512646D0 (en) Treatment of gases
HU0400952D0 (en) Treatment of anus-cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
17P Request for examination filed

Effective date: 20071004

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

A4 Supplementary search report drawn up and despatched

Effective date: 20101227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110726